Abstract
Abstract The paradigm shift that is attempting to change the way pharmaceutical manufacturing is undertaken in the 21 st century has raised practical challenges for the adoption and implementation of the Process Analytical Technology (PAT) framework initiated by the U.S. Food and Drug Administration (FDA). The motive is to engender a science-oriented pharmaceutical manufacturing that is along FDA's pharmaceutical product quality by design (QbD) ideology. One such challenge revolves around the integration of PAT technologies such as varied process analytics (e.g. sensors, spectrometry, chromatography, etc.), multivariate analyses, knowledge management, and process control under a common information exchange and data-logging platform. Such an integrated platform was recently installed and commissioned at the Kilo-Lab in the Institute of Chemical and Engineering Sciences (ICES). Its efficacy was demonstrated through synthesizing 4-D-erythronolactone at kilo-scale using a four-phase hybrid process.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
